Latest News

Read the May 2023 edition of FH Europe’s Heart Beat newsletter to stay up to date with the latest news and events: HoFH Patient Ambassadors advocate at the WHF Rare CVDs Forum. EAS Annual Congress follow-up webinars. Biggest patient organization celebrates their 20th anniversary. Story of a young man, husband and a father with Lp(a) […]

An international community of multidisciplinary stakeholders committed to making lives of people with rare cardiovascular diseases “longer and better” came together at the Rare Cardiovascular Diseases Forum (CVDs). FH Europe together with the HoFH community was actively involved in the meeting’s design and preparation as well as delivery onsite. The meeting was held on 17th […]

Wow, what a day!  On 28th April FH Europe attended the 20th anniversary event for EPF (The European Patient’s Forum). The day focused on EPF past, present and future, asking attendees challenging and thought provoking questions through a series of workshops around patient advocacy across policy and advocacy campaigns, building capacity in the patient community, […]

Read the April 2023 edition of FH Europe’s Heart Beat newsletter to stay up to date with the latest news and events: – Introducing Emma and Elsie, new FH Europe team members Free registration until May 15 for the upcoming EAS Congress Take a survey to influence new treatments: HoFH lived experience survey FH Europe […]

Knowledge about how HoFH impacts people’s lives is scarce. There have been limited studies conducted to understand how this ultra-rare condition affects diagnosed individuals and their family members, who often act as caregivers. Having identified this knowledge gap, FH Europe was pleased to be involved in the development of a survey supporting a research project […]

Welcome Emma Print and Elsie Evans! They join FH Europe to strengthen and widen our community engagement while providing more opportunities for support and education for the Network Organizations, individual patients and Patient Ambassadors across Europe and beyond.